Jazz Pharmaceuticals plc (JAZZ)
| Market Cap | 10.31B |
| Revenue (ttm) | 4.16B |
| Net Income (ttm) | -368.48M |
| Shares Out | 60.77M |
| EPS (ttm) | -6.06 |
| PE Ratio | n/a |
| Forward PE | 7.62 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 909,020 |
| Open | 168.63 |
| Previous Close | 166.91 |
| Day's Range | 167.36 - 171.51 |
| 52-Week Range | 95.49 - 182.99 |
| Beta | 0.31 |
| Analysts | Strong Buy |
| Price Target | 194.40 (+14.56%) |
| Earnings Date | Nov 5, 2025 |
About JAZZ
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enry... [Read more]
Financial Performance
In 2024, Jazz Pharmaceuticals's revenue was $4.07 billion, an increase of 6.12% compared to the previous year's $3.83 billion. Earnings were $560.12 million, an increase of 35.02%.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for JAZZ stock is "Strong Buy." The 12-month stock price target is $194.4, which is an increase of 14.56% from the latest price.
News
Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting
New interim results from the EpiCom trial, a prospective evaluation of behavioral outcomes in patients with tuberous sclerosis complex, suggest improvements in non-seizure outcomes Eight abstracts, in...
Trials, Sales Wins Sends Jazz Pharmaceuticals Higher
Jazz Pharmaceuticals PLC (JAZZ) shares up 352% since Big Money bought big in 2015.
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium
Late-breaking HERIZON-GEA-01 presentation highlights the expanding clinical profile of Ziihera across HER2-driven gastrointestinal cancers Jazz to host investor webcast on Friday, January 9, 2026, to ...
Jazz Pharmaceuticals plc (JAZZ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Jazz Pharmaceuticals plc (JAZZ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
DUBLIN , Nov. 18, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in Citi's 2025 Global Healthcare Conference. Company management will pa...
Jazz Pharmaceuticals: Stock Soars On Zanidatamab Data - I'm Still On The Fence
Jazz Pharmaceuticals plc surged over 20% after positive Phase 3 data for Ziihera in HER2+ gastroesophageal cancer. JAZZ's diversified portfolio, strong Q3 earnings, and upgraded 2025 revenue guidance ...
Jazz Pharmaceuticals' And Zymeworks' Ziihera Success: A Pleasant Surprise
Jazz Pharmaceuticals plc and Zymeworks Inc. announced positive topline phase 3 results for Ziihera in HER2-positive gastroesophageal adenocarcinoma. Ziihera in combination with chemotherapy and in com...
Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans
Zymeworks Inc. (NASDAQ: ZYME) stock is surging on Monday, with a session volume of 2.17 million, compared to an average volume of 728.75K, according to Benzinga Pro.
Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar.
The companies' drug Ziihera shows clinically meaningful benefits for patients with gastroesophageal adenocarcinoma.
Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinom
Ziihera plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful effect with a strong trend to...
Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso™ (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025
Data highlight continued progress in Jazz's brain tumor research and demonstrate the company's commitment to advancing treatment options for patients with rare and aggressive brain tumors For U.S. med...
Jazz Pharmaceuticals plc (JAZZ) Q3 2025 Earnings Call Transcript
Jazz Pharmaceuticals plc ( JAZZ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Jack Spinks - Executive Director of Investor Relations Renée Galá - President, CEO & Director ...
Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance
– Modeyso™ approved as the first and only treatment for recurrent H3 K27M-mutant DMG – – Zepzelca ® and atezolizumab (Tecentriq ®) combination approved as maintenance therapy in 1L ES-SCLC – – 3Q25 t...
Aristotle Global Equity Advisory Q3 2025 Contributors And Detractors
MonotaRO, the Japanese business-to-business (B2B) e-commerce platform, was the largest detractor during the quarter. Pawn shop operator FirstCash was the top contributor during the quarter. Aggregates...
Jazz Pharmaceuticals Appoints Ted W. Love, M.D.
Dr. Love, a biopharmaceutical industry veteran, brings extensive executive leadership and board experience with proven success in creating shareholder value DUBLIN , Oct. 28, 2025 /PRNewswire/ -- Jazz...
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025
DUBLIN , Oct. 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 third quarter financial results on Wednesday, November 5, 2025, after the cl...
Iambic Announces Research Collaboration with Jazz Pharmaceuticals for IAM1363 and Zanidatamab Combination Cohort in HER2-Positive Breast Cancer
SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, announced it ha...
3 Small Cap Stocks To Play As The Bantamweights Break Out On Wall Street
The S&P 600 Small Cap Index is only up 2.0% year-to-date, but the small-cap trajectory is trending to the upside, with the index returning 5.8% since July.
FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal Phase 3 IMforte trial Zepzelca and atezolizumab combination added to National Comprehensive Canc...
US FDA approves Jazz Pharma's therapy for lung cancer
The U.S. Food and Drug Administration on Thursday has expanded the approval for Jazz Pharmaceuticals' therapy as a maintenance treatment of adult patients with a type of lung cancer.
Jazz Pharmaceuticals Announces Promising Xywav Data: Why I Assign A BUY Rating
Jazz Pharmaceuticals (JAZZ) receives a BUY rating, driven by strong DUET trial results for Xywav in narcolepsy and idiopathic hypersomnia. JAZZ's growth is anchored by Xywav and Epidiolex, both genera...
Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses
20 abstracts presented across World Sleep and Psych Congresses showcase Jazz's leadership in sleep medicine Novel results from the Phase 4 DUET trial underscore the significance of appropriate treatme...
Modeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma
Modeyso, the first treatment option for this ultra-rare and aggressive brain tumor, is commercially available in the United States For U.S. media and investors only DUBLIN , Sept. 9, 2025 /PRNewswire/...
Jazz Pharmaceuticals Plc (JAZZ) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 9:30 AM EDT Company Participants Amal Melhem-Bertrandt Philip Johnson - Executive VP & CFO ...
Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference
DUBLIN , Aug. 21, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 2025 Wells Fargo Healthcare Conference. Company management will ...